Literature DB >> 11882759

Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation.

Ronnie Tung-Ping Poon1, Sheung Tat Fan, Chung Mau Lo, Chi Leung Liu, John Wong.   

Abstract

OBJECTIVE: To evaluate the survival results and pattern of recurrence after resection of potentially transplantable small hepatocellular carcinomas (HCC) in patients with preserved liver function, with special reference to the implications for a strategy of salvage transplantation. SUMMARY BACKGROUND DATA: Primary resection followed by transplantation for recurrence or deterioration of liver function has been recently suggested as a rational strategy for patients with HCC 5 cm or smaller and preserved liver function. However, there are no published data on transplantability after HCC recurrence or long-term deterioration of liver function after resection of small HCC in Child-Pugh class A patients. Such data are critical in determining the feasibility of salvage transplantation.
METHODS: From a prospective database of 473 patients with resection of HCC between 1989 and 1999, 135 patients age 65 years or younger had Child-Pugh class A chronic liver disease (chronic hepatitis or cirrhosis) and transplantable small HCC (solitary < or =5 cm or two or three tumors < or = 3 cm). Survival results were analyzed and the pattern of recurrence was examined for eligibility for salvage transplantation based on the same criteria as those of primary transplantation for HCC.
RESULTS: Overall survival rates at 1, 3, 5, and 10 years were 90%, 76%, 70%, and 35%, respectively, and the corresponding disease-free survival rates were 74%, 50%, 36%, and 22%. Cirrhosis and oligonodular tumors were predictive of worse disease-free survival. Patients with concomitant oligonodular tumors and cirrhosis had a 5-year overall survival rate of 48% and a disease-free survival rate of 0%, which were significantly worse compared with other subgroups. At a median follow-up of 48 months, 67 patients had recurrence and 53 (79%) of them were considered eligible for salvage transplantation. Decompensation from Child-Pugh class A to B or C without recurrence occurred in only six patients.
CONCLUSIONS: For Child-Pugh class A patients with small HCC, hepatic resection is a reasonable first-line treatment associated with a favorable 5-year overall survival rate. A considerable proportion of patients may survive without recurrence for 5 or even 10 years; among those with recurrence, the majority may be eligible for salvage transplantation. These data suggest that primary resection and salvage transplantation may be a feasible and rational strategy for patients with small HCC and preserved liver function. Primary transplantation may be a preferable option for the subset of patients with oligonodular tumors in cirrhotic liver in view of the poor survival results after resection.

Entities:  

Mesh:

Year:  2002        PMID: 11882759      PMCID: PMC1422443          DOI: 10.1097/00000658-200203000-00009

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  40 in total

1.  Liver transplantation for hepatocellular carcinoma.

Authors:  H Bismuth; P E Majno; R Adam
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

2.  Should hepatomas be treated with hepatic resection or transplantation?

Authors:  J Yamamoto; S Iwatsuki; T Kosuge; I Dvorchik; K Shimada; J W Marsh; S Yamasaki; T E Starzl
Journal:  Cancer       Date:  1999-10-01       Impact factor: 6.860

3.  Determination of the clonal origin of multiple human hepatocellular carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNA.

Authors:  T Yamamoto; K Kajino; M Kudo; Y Sasaki; Y Arakawa; O Hino
Journal:  Hepatology       Date:  1999-05       Impact factor: 17.425

4.  Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.

Authors:  J M Llovet; J Fuster; J Bruix
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

5.  The long-term course of chronic hepatitis B.

Authors:  V Di Marco; O Lo Iacono; C Cammà; A Vaccaro; M Giunta; G Martorana; P Fuschi; P L Almasio; A Craxì
Journal:  Hepatology       Date:  1999-07       Impact factor: 17.425

6.  Rising incidence of hepatocellular carcinoma in the United States.

Authors:  H B El-Serag; A C Mason
Journal:  N Engl J Med       Date:  1999-03-11       Impact factor: 91.245

7.  Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths.

Authors:  S T Fan; C M Lo; C L Liu; C M Lam; W K Yuen; C Yeung; J Wong
Journal:  Ann Surg       Date:  1999-03       Impact factor: 12.969

8.  Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors.

Authors:  R T Poon; S T Fan; C M Lo; C L Liu; J Wong
Journal:  Ann Surg       Date:  1999-02       Impact factor: 12.969

9.  Partial hepatectomy or orthotopic liver transplantation for the treatment of resectable hepatocellular carcinoma? A cost-effectiveness perspective.

Authors:  F P Sarasin; E Giostra; G Mentha; A Hadengue
Journal:  Hepatology       Date:  1998-08       Impact factor: 17.425

Review 10.  Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation.

Authors:  E Mor; R Tur-Kaspa; P Sheiner; M Schwartz
Journal:  Ann Intern Med       Date:  1998-10-15       Impact factor: 25.391

View more
  260 in total

Review 1.  Surgical management of hepatocellular carcinoma.

Authors:  Tony Cy Pang; Vincent Wt Lam
Journal:  World J Hepatol       Date:  2015-02-27

2.  Successful Anatomic Resection of Tumor-Bearing Portal Territory Delays Long-Term Stage Progression of Hepatocellular Carcinoma.

Authors:  Junichi Shindoh; Yuta Kobayashi; Ryosuke Umino; Kazutaka Kojima; Satoshi Okubo; Masaji Hashimoto
Journal:  Ann Surg Oncol       Date:  2020-07-25       Impact factor: 5.344

3.  Accelerated carcinogenesis following liver resection in chronically inflamed livers: A window of opportunity for treatment.

Authors:  Amir Sonnenblick; Tamar Zahavi
Journal:  Biomed Rep       Date:  2017-03-30

Review 4.  Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.

Authors:  Maurizio Pompili; Giampiero Francica; Francesca Romana Ponziani; Roberto Iezzi; Alfonso Wolfango Avolio
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

5.  Primary surgical resection versus liver transplantation for transplant-eligible hepatocellular carcinoma patients.

Authors:  Robert J Wong; James Wantuck; Antonia Valenzuela; Aijaz Ahmed; Clark Bonham; Amy Gallo; Marc L Melcher; Glen Lutchman; Waldo Concepcion; Carlos Esquivel; Gabriel Garcia; Tami Daugherty; Mindie H Nguyen
Journal:  Dig Dis Sci       Date:  2013-11-27       Impact factor: 3.199

Review 6.  Progress in the treatment of pulmonary metastases after liver transplantation for hepatocellular carcinoma.

Authors:  Zhan-Wang Xiang; Lin Sun; Guo-Hong Li; Rakesh Maharjan; Jin-Hua Huang; Chuan-Xing Li
Journal:  World J Hepatol       Date:  2015-09-18

7.  Overexpression of SPAG9 correlates with poor prognosis and tumor progression in hepatocellular carcinoma.

Authors:  Chengyao Xie; Lin Fu; Nan Liu; Qingchang Li
Journal:  Tumour Biol       Date:  2014-05-08

8.  Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection.

Authors:  Yi-Peng Fu; Yong Yi; Jin-Long Huang; Chu-Yu Jing; Jian Sun; Xiao-Chun Ni; Zhu-Feng Lu; Ya Cao; Jian Zhou; Jia Fan; Shuang-Jian Qiu
Journal:  Oncologist       Date:  2017-04-24

9.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

10.  Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.

Authors:  Jordi Rimola; Alejandro Forner; Víctor Sapena; Neus Llarch; Anna Darnell; Alba Díaz; Angeles García-Criado; Lluís Bianchi; Ramon Vilana; Álvaro Díaz-González; Carmen Ayuso; Jordi Bruix; María Reig
Journal:  Eur Radiol       Date:  2019-08-01       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.